Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

subpage banner

Overview

OVERVIEW

LEADING THE DISCOVERY of Allosteric Binding Sites to Create New Medicines



LEADING THE DISCOVERY AND DEVELOPMENT OF NEXT GENERATION ALLOSTERIC SMALL MOLECULE THERAPIES

Our mission at Gain Therapeutics is to discover and develop groundbreaking medicines that transform lives and provide hope and improved quality of life to people suffering from debilitating neurodegenerative diseases, rare genetic disorders and cancer.

Our clinical stage lead program GT-02287 has a best-in-class profile based on preclinical data and is currently being evaluated in a Phase 1 clinical trial. GT-02287 has disease-modifying potential in the treatment of Parkinson’s disease and has applications in other neurodegenerative diseases, including Gaucher disease, dementia with Lewy bodies, and Alzheimer’s disease.

Our MagellanTM drug discovery platform integrates AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models to uncover novel allosteric binding sites on disease-implicated proteins across all therapeutic areas, pinpointing pockets that cannot be found or drugged with current technologies. With Magellan, we discover novel, allosteric small molecule modulators that restore or disrupt protein function through activation, inhibition, stabilization, destabilization and targeted degradation, depending on the effect required based on the disease biology.

The allosteric mechanism of action enables us to generate first-in-class or best-in-class product candidates, and we have applied our platform to generate the entirety of our product pipeline.

Click on these links to learn more about our science, technology and programs.